Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of the Combination of GLPG2451 and GLPG2222, With or Without GLPG2737, in Adult Subjects With Cystic Fibrosis

NCT03540524 is registered in ClinicalTrials.gov with Lakefront Biotherapeutics NV as lead sponsor.

NCT NCT03540524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03540524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of the Combination of GLPG2451 and GLPG2222, With or Without GLPG2737, in Adult Subjects With Cystic Fibrosis
Lead sponsor
Lakefront Biotherapeutics NV
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2018
Completion date
March 11, 2019
Enrollment
10 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis